What type of study is this?

This is a Cross-Sectional Study study (also classified as: Quantitative Study).

September 26, 2025Cancer Immunology Research

Abstract A006: Assessment of EBV DNA methylation to guide antiviral use in EBV-associated lymphoma

View Full Paper

Ask AI

Bookmark

Patients with lower BGLF4 methylation had significantly better responses to ganciclovir (p=0.0007) in EBV+ lymphomas.
Four CpG sites in the BGLF4 region showed heterogeneous methylation, highlighting its role in predicting GCV response.
The study assessed 136 EBV+ patients, examining BGLF4 methylation as a potential biomarker for antiviral therapy suitability.
BGLF4 demethylation may signify lytic EBV activity, indicating a link to improved outcomes with ganciclovir treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Cross-sectional analysis reveals that EBV DNA methylation informs ganciclovir response in lymphomas, suggesting a potential biomarker for treatment guidance.

Cite This Study

Noël et al. (2025) studied this question.

synapsesocial.com/papers/68d6c67db1249cec298b230e https://doi.org/10.1158/2326-6074.cimm25-a006

View Full Paper

Ask AI

Bookmark

Implication

Cross-sectional analysis reveals that EBV DNA methylation informs ganciclovir response in lymphomas, suggesting a potential biomarker for treatment guidance.

Abstract A006: Assessment of EBV DNA methylation to guide antiviral use in EBV-associated lymphoma

Key Points

Discussion

Implication

Cite This Study

Abstract A006: Assessment of EBV DNA methylation to guide antiviral use in EBV-associated lymphoma

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider